Cough is a crucial protective reflex that helps protect the lungs and airways. However, when cough becomes chronic and ...

For more than a decade Bethan has been living with a chronic refractory cough, the medical term for a condition with no obvious cause. It's a common complaint thought to affect one in ten of the ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report) on January 10 and set a price ...

At the moment there are no approved therapies for suppressing refractory chronic cough, defined as lasting for eight weeks or more, which is estimated to affect somewhere between 5% and 10% of ...

Analyst Serge Belanger from Needham maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report) and keeping the price target at ...

We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a ...

BLU-5937 hit the mark in the mid-stage SOOTHE trial in refractory chronic cough towards the end of last year, after generating disappointing results in an earlier readout, and is heading for a ...

U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drive ...

The Company continues to anticipate that the totality of its early-stage research programs will comprise less than 20% of overall expenditure.

AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...